Plain-English translation of NCT06107374 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new imaging agent called that can visualize activated T cells — your body's cancer-fighting immune cells — in real time. Researchers want to see if this special scan can help predict how well your immunotherapy treatment is working and whether you might experience side effects. The goal is to give doctors a better tool to monitor your immune response during cancer treatment.
Current imaging scans can show tumor size but don't reveal how your immune system is actually responding to immunotherapy. This new imaging approach could help doctors understand which patients will benefit most from treatment and catch potential immune-related side effects early.
You would receive imaging scans using the new agent before, during, and after your immunotherapy treatment to show how your immune cells are responding. The study will track how this imaging information compares to your actual treatment outcomes and any side effects you experience. You'll need to be willing to follow up at the University of Iowa for these scans and evaluations.
AI-generated summary from trial data · Jul 21, 2026 · Not medical advice
United States